Lilly cuts Zepbound self-pay pricing to $299–$449
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most coverage omits.
The starter dose drops to $299 and higher doses to $449, on a 45-day refill condition most coverage omits.
All-in monthly cost at 10 mg
Self-pay vial pricing effective 23 February 2026 runs $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above, conditional on refilling within 45 days of the previous delivery.
Miss that window and the standard self-pay price applies for that refill, which turns a predictable brand price into an unpredictable one if a delivery slips.
At the starter dose this is competitive with several compounded programmes; at maintenance it remains roughly double the cheapest verified compounded route.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
What the spread actually represents
All-in cost runs $215 to $597 a month for the same molecule from the same category of licensed pharmacy. That gap is not the medicine. It is overhead, clinical wrap, sourcing and margin, plus how aggressively a programme is willing to structure its fees.
5 of 16 charge a mandatory recurring fee and 12 hold one price at every strength. Those two facts explain most of the spread, and neither appears in a headline figure.
Where our numbers could be wrong
A programme changed its price after our capture date. A third-party figure we recorded does not survive checking. A promotional rate was published as a standing one. Or a programme publishes something we could not find.
All four are live risks and the first is near-certain over time. Every figure carries its capture date and a link to the source we read, so the check takes about two minutes and does not require trusting us.
Why the cheapest entries are the least reliable
Four distortions push in the same direction: a promotional first month quoted as a standing rate, a prepaid bundle rate quoted as monthly, a medication figure that excludes a mandatory membership, and occasionally a different molecule's price in the wrong column.
Every one of those makes a programme look cheaper than it is, which is why the bottom of any published table is where errors concentrate. It is also why we mark which figures we read at the provider and which we did not, rather than presenting one confident list.
Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward.
How to sanity-check any figure you find elsewhere
Three questions. What dose does it describe? Does it include every recurring fee? And when was it captured? A price failing any of the three is not comparable to the numbers here, and most published figures fail at least one.
Tirzepatide makes this worse than most categories because the same molecule sells under several brands at prices spanning more than fifteenfold. 'Tirzepatide costs X' is not a sentence that can be true without naming the product and the channel.
What the head-to-head trial actually showed
SURMOUNT-5 randomised adults with obesity to tirzepatide or semaglutide and reported a larger mean reduction in body weight on tirzepatide over 72 weeks. It is the strongest direct comparison available and it is the reason many people arrive at this molecule specifically rather than at GLP-1 therapy in general.
Three caveats are worth carrying. A mean is not a prediction for an individual, and the distribution around it is wide. Trial participants received structured support most telehealth programmes do not replicate. And the trial compared maximum tolerated doses, which is a different question from what a given person will tolerate.
Read as a purchasing decision, it says the more expensive molecule does more on average. It does not say it will do more for you, and it says nothing about which programme should supply it.
Why titration is a pricing question
Tirzepatide is started at 2.5 mg weekly and increased in 2.5 mg steps at intervals of at least four weeks. The starter dose is a tolerance-building dose rather than a therapeutic one, and the gastrointestinal effects that cause most discontinuation cluster in the days after each increase.
Reaching a maintenance dose therefore takes at least eight to twelve weeks when nothing is repeated, and repeats are common rather than exceptional. Most of a first year is spent at or near maintenance, which is why every figure on this site is stated at 10 mg and why 12 of the 16 priced programmes holding one price across the ladder is a materially different offer from the rest.
The molecule, and why it costs more than semaglutide
Tirzepatide is a single peptide that activates two incretin receptors: GLP-1, which semaglutide also targets, and GIP, which it does not. Both receptors influence insulin secretion, gastric emptying and central appetite signalling, and the working hypothesis for the larger effect size is that engaging both produces effects the GLP-1 arm alone does not.
That dual action is also part of why it costs more to make. The peptide is longer and more structurally complex than semaglutide, the synthesis is harder, and the active pharmaceutical ingredient sells at a premium to compounding pharmacies. Across programmes carrying both molecules, tirzepatide typically runs forty to a hundred per cent above the same programme's semaglutide price.
The commercial consequence is that a compounded tirzepatide programme has less room to discount than a compounded semaglutide one. When a tirzepatide price looks dramatically below the market, the explanation is usually a promotional rate, a prepaid term or a starting dose rather than a cheaper supply chain.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.